Nature reported that in early trials, faulty reagents resulted in dosing miscalculations, causing early participants to receive doses that were approximately one-fifth the planned amount.
Having experienced shortages of everything from life-saving personal protective equipment to swabs and reagents for testing during the pandemic, the United States clearly needs to focus on medical supplies and key pharmaceutical ingredients.
In the earliest days, well before at-home tests were available, the country grappled with swab and reagent shortages that severely limited the number of lab-based tests it could administer.
In addition to restricting personal or business travel, these bans also restrict the flow of reagents and supplies critical for tracking the spread of the virus and treating people in a potential hot zone.